News flow
Non-Regulatory Press Releases and News
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
Invitation to presentation of Orexo´s Interim Report Q4 2022 incl. Full Year Report
Orexo initiates exploratory feasibility studies of amorphOX[®] with two leading biopharmaceutical and vaccine companies
@OrexoABpubl
3 February 2023
Life Science Sweden om att vi lämnat in en FDA-ansökan om att få OX124 - vårt överdosläkemedel - godkänt i USA.… https://t.co/pAjhD063kD
@OrexoABpubl
3 February 2023
#Orexo has filed a New Drug Application to the FDA for OX124, our life-saving medication that reverses the effects… https://t.co/WbspScyY7k
@OrexoABpubl
31 January 2023
Klas Palin, hälsovårdsanalytiker på Erik Penser Bank, i en lång intervju med VD Nikolaj Sørensen. På agendan: Opera… https://t.co/8nhwCYB7hL
Europe |
US |
|
 |
|
|
|
Lena Wange IR & Corporate Communications Director Switchboard: +46 (0)18 780 88 00 Direct phone: +46 73 064 16 36 Send email: ir@orexo.com Location: Uppsala, Sweden |
Robert A. DeLuca President Orexo US Inc. Switchboard: +1 (0)855 982 7658 Email: us.media@orexo.com Location: New Jersey, US |
Dennis Urbaniak EVP Digital Therapeutics Switchboard: +1 (0)855 982 7658 Email: us.media@orexo.com Location: New Jersey, US |
